Fortis Malar Hospitals Limited reported a standalone net profit of ₹17.71 lakh for the quarter ended June 30, 2026 (Q1FY27), marking a significant turnaround from the net loss of ₹2.98 lakh recorded in the same period last year. The consolidated net profit stood at ₹15.22 lakh compared to a loss of ₹4.50 lakh in Q1FY26. This improvement comes as the company continues to wind down its active healthcare services following the sale of its business operations, with management focusing on resolving pending legal matters and evaluating future restructuring paths.

The Board of Directors approved the unaudited financial results on August 4, 2026, during a meeting that commenced at 11:15 Hours (IST) and concluded at 14:25 Hours (IST). The results were reviewed by B S R & Co. LLP, the statutory auditor, which issued an unmodified limited review report pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial statements were prepared in accordance with Indian Accounting Standard 34 (Ind AS 34) and other generally accepted accounting principles in India.

Financial Performance Overview

The company’s total income for the quarter was driven primarily by other income, with no grant income reported. Standalone total income amounted to ₹53.47 lakh, while consolidated total income was ₹53.56 lakh. Expenses remained controlled, with employee benefits and other operational costs forming the bulk of expenditures. The absence of medical consumable purchases and depreciation expenses reflects the cessation of hospital operations.

Note: The significant variance in prior year figures is attributed to a one-time provision reversal of ₹408.20 lakh related to minimum wage revisions, as disclosed in Note 6.

Operational Status and Restructuring

A critical disclosure in the filing highlights that Fortis Malar Hospitals Limited ceased all business operations after entering into a Business Transfer Agreement (BTA) with MGM Healthcare Private Limited during FY24. The transaction involved the sale of the Malar Hospital business on a slump sale basis. Consequently, the company has no visibility of commencing new business operations in the immediate future.

Management is currently evaluating various corporate restructuring options in consultation with legal advisors and merchant bankers. Despite the lack of operational revenue, the company maintains a going concern status, citing sufficient cash and bank balances of approximately ₹3,458.92 lakh to settle obligations as they fall due. These reserves are also earmarked to address ongoing expenses and contested liabilities, including medico-legal cases (₹649.40 lakh), VAT appeals (₹254.93 lakh), GST appeals (₹22.23 lakh), and income tax appeals (₹198.83 lakh). Management assesses the financial exposure from these disputes as remote.

What the Numbers Show

The financial results underscore the transition phase of the entity. With zero revenue from core healthcare services, the profit/loss position is heavily influenced by non-operational items such as other income and tax adjustments. The sharp decline in total income from ₹460.72 lakh in Q1FY26 to ₹53.47 lakh in Q1FY27 is largely explained by the absence of the ₹408.20 lakh provision reversal recorded in the prior year. This indicates that the current profitability is not driven by operational growth but rather by the stabilization of costs post-business exit. Investors should note that the company’s future value proposition hinges entirely on the outcome of its restructuring plans and the resolution of pending legal claims.

Fortis Malar Hospitals Limited has declared the final voting results of its 35th Annual General Meeting (AGM), confirming shareholder approval for all three resolutions placed before them. The meeting, held on July 29, 2026, via Video Conferencing/Other Audio-Visual Means (VC/OAVM), saw strong support for the adoption of financial statements, the re-appointment of Chairman Daljit Singh, and the ratification of cost auditor remuneration.

The voting process was overseen by Mukesh Kumar Agarwal of Mukesh Agarwal & Co., who served as the independent scrutinizer. A total of 161 members cast their votes, representing 11,768,673 equity shares, which accounted for approximately 62.79% of the total outstanding shares as of the record date, July 22, 2026. Remote e-voting commenced on July 24, 2026, and concluded on July 28, 2026, while e-voting during the AGM remained open for 30 minutes after the meeting ended.

Resolution Outcomes

All three resolutions were passed with overwhelming majority support, primarily driven by promoter group votes which constituted the bulk of the polled shares. The detailed voting breakdown is as follows:

The first resolution concerned the receipt, consideration, and adoption of the Audited Financial Statements (Standalone and Consolidated) for the financial year ended March 31, 2026, along with the Reports of the Board of Directors and Auditors. This ordinary resolution received 11,767,875 votes in favor and only 798 votes against.

The second resolution sought to appoint a director in place of Mr. Daljit Singh (DIN: 00135414), who retires by rotation and offered himself for re-election. This measure was approved with 11,767,290 votes in favor and 1,383 votes against. The third resolution, also ordinary, ratified the remuneration of the Cost Auditors for FY26, securing 11,767,389 votes in favor against 1,284 votes against.

Governance and Participation

The AGM was presided over by Chairman Daljit Singh. Company Secretary Vinti Verma informed attendees that there were no qualifications, observations, or adverse remarks in the reports of the Statutory Auditor or Secretarial Auditor. Authorized representatives from the Statutory Auditors, Secretarial Auditors, and Internal Auditors participated in the proceedings to address any queries.

Participation was largely virtual, with one promoter member and 80 public members attending through video conferencing. No shareholders attended in person or through proxy. The promoters and promoter group held 11,752,402 shares and voted entirely in favor of all resolutions. Public non-institutional shareholders, holding 6,971,334 shares, had a lower participation rate, with only 16,271 shares polled. Among these public votes, support ranged from 91.50% to 95.10% across the resolutions, indicating minor dissent compared to the unanimous promoter stance.

The company complied with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, by submitting the voting results to BSE Limited. The proceedings adhered to Ministry of Corporate Affairs circulars permitting VC/OAVM meetings, ensuring regulatory compliance throughout the process.